Fig. 2From: Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting systemCharacteristics of the reports of elacestrant-related adverse events (AEs) obtained from the FAERS databaseBack to article page